Embecta (NASDAQ:EMBC) Updates FY 2026 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.800-1.900 for the period, compared to the consensus earnings per share estimate of 1.600. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Zacks Research upgraded Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Wall Street Zen downgraded Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. BTIG Research lowered Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Weiss Ratings cut Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday. Finally, Mizuho cut their price objective on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Three investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $11.00.

Embecta Stock Up 26.3%

EMBC stock opened at $4.42 on Friday. The firm has a market cap of $262.24 million, a PE ratio of 2.33 and a beta of 0.81. The business has a 50 day moving average of $3.34 and a 200-day moving average of $6.66. Embecta has a 12-month low of $2.77 and a 12-month high of $15.55.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The company had revenue of $271.70 million during the quarter, compared to the consensus estimate of $254.53 million. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.Embecta’s revenue was down 8.1% on a year-over-year basis. During the same period last year, the business posted $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, research analysts expect that Embecta will post 1.62 earnings per share for the current year.

Embecta Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be given a dividend of $0.01 per share. The ex-dividend date of this dividend is Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.9%. Embecta’s dividend payout ratio (DPR) is currently 2.11%.

More Embecta News

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
• Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
• Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
• Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
• Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
• Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. VARCOV Co. purchased a new stake in Embecta in the fourth quarter worth $179,000. Bridgefront Capital LLC bought a new stake in shares of Embecta in the fourth quarter valued at $182,000. CIBC Bancorp USA Inc. purchased a new position in shares of Embecta during the 3rd quarter valued at $192,000. FourThought Financial Partners LLC purchased a new position in shares of Embecta during the 3rd quarter valued at $155,000. Finally, Vestcor Inc bought a new position in shares of Embecta during the 3rd quarter worth $204,000. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.